{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:58:01Z","timestamp":1793735881954,"version":"4.6.1"},"reference-count":17,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"unspecified","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["DKTK ED003"],"award-info":[{"award-number":["DKTK ED003"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008349","name":"Universit\u00e4t Duisburg-Essen","doi-asserted-by":"publisher","award":["Open Access Publication Fund"],"award-info":[{"award-number":["Open Access Publication Fund"]}],"id":[{"id":"10.13039\/501100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2025,12,29]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:p>Merkel cell carcinoma (MCC) exemplifies the paradigm of immunogenic tumors that nonetheless develop sophisticated immune evasion mechanisms. This is in line with the observation that MCC exhibits remarkable susceptibility to immune checkpoint inhibitors (ICIs), with responses in approximately half of patients with advanced disease in the first-line setting. However, 40\u201350% of patients show primary ICI resistance, while 20\u201330% of patients develop acquired ICI resistance on initial disease control. Still, the advent of ICI therapy represents a revolutionary rather than evolutionary advance in MCC management, fundamentally transforming outcomes from the dismal prognosis associated with conventional chemotherapy to durable responses extending substantially beyond 2 years. Still, important questions remain: (1) Is programmed cell death protein-1 or programmed death-ligand 1 inhibition more effective? (2) How long should ICI treatment continue? (3) What is the best choice of salvage therapy for patients with primary or acquired ICI resistance? (4) Which combination regimens can increase the share of patients benefiting from ICI? (5) Which patient\/tumor characteristics predict response and its duration? Finally, (6) which timing of ICI therapy, that is, the neoadjuvant, adjuvant or therapeutic setting, offers the optimal overall outcomes for patients with MCC? A number of recent studies provide initial, but unfortunately not yet definitive answers.<\/jats:p>","DOI":"10.1136\/jitc-2025-014090","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T15:50:26Z","timestamp":1768319426000},"page":"e014090","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Merkel cell carcinoma immunotherapy: key questions in the era of immune checkpoint blockade"],"prefix":"10.1136","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9183-653X","authenticated-orcid":false,"given":"J\u00fcrgen C","family":"Becker","sequence":"first","affiliation":[{"name":"Translational Skin Cancer Research (TSCR), Department of Dermatology and West German Cancer Center, University of Duisburg-Essen, Essen, Germany"},{"name":"German Cancer Consortium (DKTK), Deutsches Krebsforschungsinstitut, Heidelberg, Germany"},{"name":"Dermatology, University Hospital Essen, Essen, Nordrhein-Westfalen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6930-2694","authenticated-orcid":false,"given":"Georg","family":"Lodde","sequence":"additional","affiliation":[{"name":"Dermatology, University Hospital Essen, Essen, Nordrhein-Westfalen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6720-7570","authenticated-orcid":false,"given":"Maximilian","family":"Haist","sequence":"additional","affiliation":[{"name":"Dermatology, University Medical Center Mainz, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selma","family":"Ugurel","sequence":"additional","affiliation":[{"name":"Dermatology, Medical School and University Medical Center OWL, Klinikum Bielefeld Rosenh\u00f6he, Bielefeld, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,1,13]]},"reference":[{"key":"2026011307453931000_14.1.e014090.1","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s40257-024-00858-z","article-title":"Merkel Cell Carcinoma: Integrating Epidemiology, Immunology, and Therapeutic Updates","volume":"25","author":"Becker","year":"2024","journal-title":"Am J Clin Dermatol"},{"key":"2026011307453931000_14.1.e014090.2","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-012660","article-title":"Real-world outcomes of patients receiving salvage therapies for immune checkpoint inhibitor-resistant Merkel cell carcinoma: a rationale for future clinical trials","volume":"13","author":"Ch\u2019en","year":"2025","journal-title":"J Immunother Cancer"},{"key":"2026011307453931000_14.1.e014090.3","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.2217\/fon-2017-0072","article-title":"Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma","volume":"13","author":"Nghiem","year":"2017","journal-title":"Future Oncol"},{"key":"2026011307453931000_14.1.e014090.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.03.006"},{"key":"2026011307453931000_14.1.e014090.5","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.0077","article-title":"Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial","volume":"4","author":"D\u2019Angelo","year":"2018","journal-title":"JAMA Oncol"},{"key":"2026011307453931000_14.1.e014090.6","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/S0140-6736(22)01659-2","article-title":"Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial","volume":"400","author":"Kim","year":"2022","journal-title":"Lancet"},{"key":"2026011307453931000_14.1.e014090.7","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1200\/JCO-24-02138","article-title":"Nivolumab With or Without Ipilimumab in Patients With Recurrent or Metastatic Merkel Cell Carcinoma: A Nonrandomized, Open-Label, International, Multicenter Phase I\/II Study","volume":"43","author":"Bhatia","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026011307453931000_14.1.e014090.8","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005930","article-title":"Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma: a multicenter study of the prospective skin cancer registry ADOREG","volume":"10","author":"Glutsch","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026011307453931000_14.1.e014090.9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2690"},{"key":"2026011307453931000_14.1.e014090.10","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009803","article-title":"Intratumoral STING agonist reverses immune evasion in PD-(L)1-refractory Merkel cell carcinoma: mechanistic insights from detailed biomarker analyses","volume":"12","author":"Pulliam","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2026011307453931000_14.1.e014090.11","doi-asserted-by":"crossref","DOI":"10.3390\/jpm13050841","article-title":"Introducing Radiotherapy in Metastatic Merkel Cell Carcinoma Patients with Limited Progression on Avelumab: An Effective Step against Primary and Secondary Immune Resistance?","volume":"13","author":"Ferini","year":"2023","journal-title":"J Pers Med"},{"key":"2026011307453931000_14.1.e014090.12","doi-asserted-by":"crossref","first-page":"6079","DOI":"10.1245\/s10434-024-15478-4","article-title":"The Role of Neoadjuvant Immunotherapy in the Management of Merkel Cell Carcinoma with Clinically Detected Regional Lymph Node Metastasis","volume":"31","author":"Chang","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"2026011307453931000_14.1.e014090.13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00769-9"},{"key":"2026011307453931000_14.1.e014090.14","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1093\/jnci\/djad125","article-title":"Evaluating relapse-free survival as an endpoint for overall survival in adjuvant immunotherapy trials","volume":"115","author":"Li","year":"2023","journal-title":"J Natl Cancer Inst"},{"key":"2026011307453931000_14.1.e014090.15","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-012123","article-title":"Risk of disease progression after discontinuing immunotherapy in 105 patients with Merkel cell carcinoma who responded to PD-1 pathway blockade","volume":"13","author":"Tachiki","year":"2025","journal-title":"J Immunother Cancer"},{"key":"2026011307453931000_14.1.e014090.16","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/cncr.35050","article-title":"Avelumab treatment for patients with metastatic Merkel cell carcinoma can be safely stopped after 1 year and a PET\/CT-confirmed complete response","volume":"130","author":"Zijlker","year":"2024","journal-title":"Cancer"},{"key":"2026011307453931000_14.1.e014090.17","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ejca.2023.01.016","article-title":"Durability of response to immune checkpoint inhibitors in metastatic Merkel cell carcinoma after treatment cessation","volume":"183","author":"Weppler","year":"2023","journal-title":"Eur J Cancer"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-014090","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T15:50:28Z","timestamp":1768319428000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-014090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,13]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/jitc-2025-014090"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-014090","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}